Riskpilot← Back to searchSign inGet full accessTEVA NORWAY AS
ASActiveOrg 982222311Kinoveien 3A, 1337 SandvikaWholesale of pharmaceutical and medical goods · NACE 4646Est. 200015 employees
Revenue 2024
NOK 495,3M
+11% vs 2023
EBITDA margin
3.3%
-2% vs 2023
Equity ratio
23.0%
Financial strength
Net profit 2024
NOK 11,3M
+13% vs 2023
| Revenue | NOK 495,3M | +11% |
| EBITDA | NOK 16,2M | -2% |
| Net profit | NOK 11,3M | +13% |
| Total assets | NOK 230,5M | -15% |
| Equity | NOK 52,9M | +27% |
| Employees | 15 | — |
Legal name
TEVA NORWAY AS
Org number
982222311
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. juli 2000
Share capital
NOK 7 100 000
Employees
15 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap eller daglig leder og ett styremedlem i fellesskap.
Company purpose
Salg og markedsføring av farmasøytiske og helse produkter.
Address
Kinoveien 3A, 1337 Sandvika
Phone
+4766775590
Email
post@tevapharm.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 286 039 | 320 505 | 368 340 | 445 967 | 495 339 |
| Staff expenses | −18 532 | −17 752 | −16 660 | −17 640 | −21 386 |
| EBITDA | 11 659 | 17 125 | 16 771 | 16 613 | 16 222 |
| Depreciation & amort. | −9 588 | −6 315 | −1 431 | −1 429 | −1 412 |
| EBIT | 2 071 | 10 810 | 15 340 | 15 184 | 14 809 |
| Net financials | −2 011 | −1 851 | −1 625 | −2 227 | −201 |
| Profit before tax | 60 | 8 959 | 13 715 | 12 957 | 14 608 |
| Tax | 1 765 | 2 994 | 3 070 | 2 917 | 3 300 |
| Net profit | −1 705 | 5 965 | 10 645 | 10 040 | 11 309 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 210 862 | 180 201 | 188 726 | 269 649 | 230 450 |
| Equity | 14 951 | 20 916 | 31 561 | 41 602 | 52 910 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 195 911 | 159 285 | 157 165 | 228 047 | 177 540 |
| Total debt | 195 911 | 159 285 | 157 165 | 228 047 | 177 540 |
EBITDA margin
3.3%
This company
15.8%
Market median
-79% vs market
20202024
Equity ratio
23.0%
This company
38.2%
Market median
-40% vs market
20202024
Return on equity
21.4%
This company
18.4%
Market median
+16% vs market
20202024
Net profit margin
2.3%
This company
8.1%
Market median
-72% vs market
20202024
Asset turnover
2.15×
This company
1.12×
Market median
+92% vs market
20202024
Debt / equity
3.36×
This company
0.62×
Market median
-442% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2025 | |
| Board of Directors | 2021 | |
| Former (1) | ||
| Chairman | 2021 – 2025 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Teva Pharmaceuticals Europe B.V | Company | 100% | 100% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TEVA NORWAY AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Morten Hamar | Chairman | 0 companies |
| Kim Vallentin Peetz | Board of Directors | 0 companies |
| Jan Willem Scheer | Chairman | 0 companies |